AbCellera Biologics Inc. Increase (Decrease) in Deferred Revenue
AbCellera Biologics Inc. (ABCL) reported Increase (Decrease) in Deferred Revenue of $44.13 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2026-08-05
- AbCellera Biologics Inc. increase (decrease) in deferred revenue for the quarter ending 2026-06-30 was $52.16M.
- AbCellera Biologics Inc. increase (decrease) in deferred revenue for the quarter ending 2026-03-31 was -$8.03M, a 160.34% decline year-over-year.
- AbCellera Biologics Inc. increase (decrease) in deferred revenue for the quarter ending 2025-12-31 was -$4.51M, a 181.38% decline year-over-year.
- AbCellera Biologics Inc. increase (decrease) in deferred revenue for the quarter ending 2025-09-30 was -$7.04M.
- AbCellera Biologics Inc. increase (decrease) in deferred revenue for fiscal 2025 was -$2.19M.
- AbCellera Biologics Inc. increase (decrease) in deferred revenue for fiscal 2024 was -$7.93M.
- AbCellera Biologics Inc. increase (decrease) in deferred revenue for fiscal 2023 was -$13.98M, a 326.04% decline from fiscal 2022.
- AbCellera Biologics Inc. increase (decrease) in deferred revenue for fiscal 2022 was $6.18M, a 28.30% decline from fiscal 2021.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | $52.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $44.13M 10-Q · filed 2026-08-05 | $39.62M derived: sum of 3 quarters · filed 2026-08-05 | $32.57M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$8.03M 10-Q · filed 2026-05-11 | -$12.54M derived: sum of 2 quarters · filed 2026-05-11 | -$19.59M derived: sum of 3 quarters · filed 2026-05-11 | -$23.54M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$4.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$11.56M derived: sum of 2 quarters · filed 2026-02-24 | -$15.51M derived: sum of 3 quarters · filed 2026-08-05 | -$2.19M 10-K · filed 2026-02-24 |
| 2025-09-30 | -$7.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$11.00M derived: sum of 2 quarters · filed 2026-08-05 | $2.32M 10-Q · filed 2025-11-06 | $7.86M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$3.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $9.36M 10-Q · filed 2026-08-05 | $14.90M derived: sum of 3 quarters · filed 2026-08-05 | $14.21M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $13.31M 10-Q · filed 2026-05-11 | $18.86M derived: sum of 2 quarters · filed 2026-05-11 | $18.16M derived: sum of 3 quarters · filed 2026-05-11 | $13.40M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $5.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $4.85M derived: sum of 2 quarters · filed 2026-02-24 | $86.00K derived: sum of 3 quarters · filed 2026-02-24 | -$7.93M 10-K · filed 2026-02-24 |
| 2024-09-30 | -$692.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$5.46M derived: sum of 2 quarters · filed 2025-11-06 | -$13.47M 10-Q · filed 2025-11-06 | -$20.21M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | -$4.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$12.78M 10-Q · filed 2025-08-07 | -$19.52M derived: sum of 3 quarters · filed 2026-02-24 | -$21.89M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | -$8.02M 10-Q · filed 2025-05-08 | -$14.76M derived: sum of 2 quarters · filed 2026-02-24 | -$17.12M derived: sum of 3 quarters · filed 2026-02-24 | -$18.09M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | -$6.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$9.11M derived: sum of 2 quarters · filed 2026-02-24 | -$10.07M derived: sum of 3 quarters · filed 2026-02-24 | -$13.98M 10-K · filed 2026-02-24 |
| 2023-09-30 | -$2.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | -$3.33M derived: sum of 2 quarters · filed 2024-11-04 | -$7.24M 10-Q · filed 2024-11-04 | $3.04M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$965.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$4.87M 10-Q · filed 2024-08-06 | $5.41M derived: sum of 3 quarters · filed 2025-02-27 | $4.29M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$3.90M 10-Q · filed 2024-05-07 | $6.37M derived: sum of 2 quarters · filed 2025-02-27 | $5.26M derived: sum of 3 quarters · filed 2025-02-27 | $1.34M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $10.28M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $9.16M derived: sum of 2 quarters · filed 2025-02-27 | $5.24M derived: sum of 3 quarters · filed 2025-02-27 | $6.18M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$1.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$5.04M derived: sum of 2 quarters · filed 2023-11-02 | -$4.09M 10-Q · filed 2023-11-02 | -$4.52M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | -$3.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$2.98M 10-Q · filed 2023-08-03 | -$3.41M derived: sum of 3 quarters · filed 2024-02-20 | $797.00K derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $941.00K 10-Q · filed 2023-05-04 | $514.00K derived: sum of 2 quarters · filed 2024-02-20 | $4.72M derived: sum of 3 quarters · filed 2024-02-20 | $3.48M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | -$427.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $3.78M derived: sum of 2 quarters · filed 2024-02-20 | $2.54M derived: sum of 3 quarters · filed 2024-02-20 | $8.62M 10-K · filed 2024-02-20 |
| 2021-09-30 | $4.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $2.96M derived: sum of 2 quarters · filed 2022-11-08 | $9.05M 10-Q · filed 2022-11-08 | $8.43M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | -$1.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $4.85M 10-Q · filed 2022-08-09 | $4.23M derived: sum of 3 quarters · filed 2023-02-21 | $2.22M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $6.09M 10-Q · filed 2022-05-10 | $5.46M derived: sum of 2 quarters · filed 2023-02-21 | $3.46M derived: sum of 3 quarters · filed 2023-02-21 | $220.00K derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | -$621.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | -$2.63M derived: sum of 2 quarters · filed 2023-02-21 | -$5.87M derived: sum of 3 quarters · filed 2023-02-21 | $21.81M 10-K · filed 2023-02-21 |
| 2020-09-30 | -$2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$5.25M derived: sum of 2 quarters · filed 2021-11-10 | $22.43M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$3.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $24.43M 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $27.68M 10-Q · filed 2021-05-14 | |||
| 2019-12-31 | -$6.00K 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |